1060811-65-5 Usage
Uses
Used in Pharmaceutical Industry:
3-Pyridinecarboxylic acid, 4-aMino-6-chlorois used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Pyridinecarboxylic acid, 4-aMino-6-chlorois used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its chemical properties allow for the creation of effective and targeted agrochemicals to protect crops and enhance agricultural productivity.
Used in Organic Chemistry Research:
3-Pyridinecarboxylic acid, 4-aMino-6-chlorois utilized in organic chemistry research for the exploration of new synthetic pathways and the development of novel chemical compounds. Its unique structure and reactivity make it an interesting subject for study and potential applications in various chemical processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1060811-65-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,0,8,1 and 1 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1060811-65:
(9*1)+(8*0)+(7*6)+(6*0)+(5*8)+(4*1)+(3*1)+(2*6)+(1*5)=115
115 % 10 = 5
So 1060811-65-5 is a valid CAS Registry Number.
1060811-65-5Relevant academic research and scientific papers
HYDANTOIN DERIVATIVE
-
Paragraph 0747, (2021/03/13)
A compound represented by general formula (I-a) : has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.
KRAS G12C INHIBITORS
-
Paragraph 0752, (2020/07/25)
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
WNT SIGNALING INHIBITOR
-
Paragraph 0231-0232, (2016/07/05)
A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n1A represents
